Mucin core polypeptide expression in the progression of neoplasia in Barrett's esophagus

Human Pathology

Volumn 37, Issue 10, 2006, Pages 1304-1315

  Glickman, Jonathan N ^a   Blount, Patricia L ^b   Sanchez, Carissa A ^b   Cowan, David S ^b   Wongsurawat, V Jon ^b   Reid, Brian J ^b,c   Odze, Robert D ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Barrett's esophagus; Dysplasia; Immunohistochemistry; Mucins

Indexed keywords

ANTIBODY; MUCIN; MUCIN 1; MUCIN 2; MUCIN 3; MUCIN 6;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DYSPLASIA; ENDOSCOPIC BIOPSY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTESTINE EPITHELIUM; MALE; METAPLASIA; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; STAINING; STATISTICAL SIGNIFICANCE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BARRETT ESOPHAGUS; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; MUCINS; NEOPLASM PROTEINS; PEPTIDES; PRECANCEROUS CONDITIONS; TUMOR MARKERS, BIOLOGICAL;

EID: 33748615718     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2006.03.023     Document Type: Article

References (32)

1. Spechler S.J. Barrett's esophagus. N Engl J Med 346 (2002) 836-842
2. Sampliner R.E. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 93 (1998) 1028-1032
3. Goldblum J.R. Barrett's esophagus and Barrett's-related dysplasia. Mod Pathol 16 (2003) 316-324
4. Skacel M., Petras R.E., Rybicki L.A., et al. p53 expression in low grade dysplasia in Barrett's esophagus: correlation with interobserver agreement and disease progression. Am J Gastroenterol 97 (2002) 2508-2513
5. Reid B.J., Blount P.L., and Rabinovitch P.S. Biomarkers in Barrett's esophagus. Gastrointest Endosc Clin N Am 13 (2003) 369-397
6. Gulizia J.M., Wang H., Antonioli D., et al. Proliferative characteristics of intestinalized mucosa in the distal esophagus and gastroesophageal junction (short-segment Barrett's esophagus): a case control study. Hum Path 30 (1999) 412-418
7. Whittles C.E., Biddlestone L.R., Burton A., et al. Apoptotic and proliferative activity in the neoplastic progression of Barrett's oesophagus: a comparative study. J Pathol 187 (1999) 535-540
8. Reid B.J., Levine D.S., Longton G., Blount P.L., and Rabinovitch P.S. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 95 (2000) 1669-1676
9. Reid B.J., Prevo L.J., Galipeau P.C., et al. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol 96 (2001) 2839-2848
10. Corfield A.P., Myerscough N., Longman R., et al. Mucins and mucosal protection in the gastrointestinal tract: new prospects for mucins in the pathology of gastrointestinal disease. Gut 47 (2000) 589-594
11. Jass J.R. Mucin core proteins as differentiation markers in the gastrointestinal tract. Histopathology 37 (2000) 561-564
12. Carrato C., Balague C., de Bolos C., et al. Differential apomucin expression in normal and neoplastic human gastrointestinal tissues. Gastroenterology 107 (1994) 160-172
13. Winterford C.M., Walsh M.D., Leggett B.A., and Jass J.R. Ultrastructural localization of epithelial mucin core proteins in colorectal tissues. J Histochem Cytochem 47 (1999) 1063-1074
14. Audie J.P., Janin A., Porchet N., et al. Expression of human mucin genes in respiratory, digestive, and reproductive tracts ascertained by in situ hybridization. J Histochem Cytochem 41 (1993) 1479-1485
15. Ho S.B., Shekels L.L., Toribara N.W., et al. Mucin gene expression in normal, preneoplastic, and neoplastic human gastric epithelium. Cancer Res 55 (1995) 2681-2690
16. Glickman J.N., Shahsafaei A., and Odze R.D. Mucin core polypeptide expression can help differentiate Barrett's esophagus from intestinal metaplasia of the stomach. Am J Surg Pathol 27 (2003) 1357-1365
17. Guillem P., Billeret V., Buisine M.P., et al. Mucin gene expression and cell differentiation in human normal, premalignant and malignant esophagus. Int J Cancer 88 (2000) 856-861
18. Chinyama C.N., Marshall R.EK., Owen W.J., et al. Expression of MUC1 and MUC2 mucin gene products in Barrett's metaplasia, dysplasia and adenocarcinoma: an immunopathological study with clinical correlation. Histopathology 35 (1999) 517-524
19. Flucke U., Steinborn E., Dries V., et al. Immunoreactivity of cytokeratins (CK7, CK20) and mucin peptide core antigens (MUC1, MUC2, MUC5AC) in adenocarcinomas, normal and metaplastic tissues of the distal oesophagus, oesophago-gastric junction and proximal stomach. Histopathology 43 (2003) 127-134
20. Reid B.J., Haggitt R.C., Rubin C.E., et al. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Path 19 (1988) 166-178
21. Lauwers G.Y., Kandemir O., Kubilis P.S., and Scott G.V. Cellular kinetics in Barrett's epithelium carcinogenic sequence: roles of apoptosis, bcl-2 protein, and cellular proliferation. Mod Pathol 10 (1997) 1201-1208
22. Piazuelo M.B., Haque S., Delgado A., Du J.X., Rodriguez F., and Correa P. Phenotypic differences between esophageal and gastric intestinal metaplasia. Mod Pathol 17 (2004) 62-74
23. Warson C., Van De Bovemkamp J.H., Korteland-van Male A.M., et al. Barrett's esophagus is characterized by expression of gastric-type mucins (MUC5AC, MUC6) and TFF peptides (TFF1 and TFF2), but the risk of carcinoma development may be indicated by the intestinal-type mucin, MUC2. Hum Path 33 (2002) 660-668
24. Arul G.S., Moorghen M., Myerscough N., et al. Mucin gene expression in Barrett's oesophagus: an in situ hybridisation and immunohistochemical study. Gut 47 (2000) 753-761
25. Endo T., Tamaki K., Arimura Y., et al. Expression of sulfated carbohydrate chain and core peptides of mucin detected by monoclonal antibodies in Barrett's esophagus and esophageal adenocarcinoma. J Gastroenterol 33 (1998) 811-815
26. Ho S.B., Shekels L.L., Toribara N.W., et al. Mucin gene expression in normal, preneoplastic, and neoplastic human gastric epithelium. Cancer Res 55 (1995) 2681-2690
27. Monges G.M., Mathoulin-Portier M.P., Acres R.B., et al. Differential MUC1 expression in normal and neoplastic human pancreatic tissue. An immunohistochemical study of 60 samples. Am J Clin Pathol 112 (1999) 635-640
28. Luttges J., Feyerabend B., Buchelt T., et al. The mucin profile of noninvasive and invasive mucinous cystic neoplasms of the pancreas. Am J Surg Pathol 26 (2002) 466-471
29. Adsay N.V., Merati K., Andea A., et al. The dichotomy in the preinvasive neoplasia to invasive carcinoma sequence in the pancreas: differential expression of MUC1 and MUC2 supports the existence of two separate pathways of carcinogenesis. Mod Pathol 15 (2002) 1087-1095
30. Nakamori S., Ota D.M., Cleary K.R., Shirotani K., and Irimura T. MUC1 mucin expression as a marker of progression and metastasis of human colorectal carcinoma. Gastroenterology 106 (1994) 353-361
31. Baldus S.E., Monig S.P., Huxel S., et al. MUC1 and nuclear beta-catenin are coexpressed at the invasion front of colorectal carcinomas and are both correlated with tumor prognosis. Clin Cancer Res 10 (2004) 2790-2796
32. Akyurek N., Akyol G., Dursun A., et al. Expression of MUC1 and MUC2 mucins in gastric carcinomas: their relationship with clinicopathologic parameters and prognosis. Pathol Res Pract 198 (2002) 665-674